BioSante Pharmaceuticals Announces Positive Bird Flu Results Using Proprietary Vaccine Adjuvant in Pre-Clinical Study (Business Wire via Yahoo! Finance) LINCOLNSHIRE, Ill.----BioSante Pharmaceuticals, Inc. today announced positive results of a dose ranging pre-clinical study demonstrating that its calcium phosphate nanoparticle-based vaccine adjuvant, BioVant, may serve as a vaccine adjuvant for the development of an effective vaccine against H5N1 avian flu, widely known as bird flu. [News Source]